REGULATORY
CEFP Kicks Off FY2018 Budget Debate with Major Focus on Scope of Off-Year Price Survey, Revision
The health minister and members of the Council on Economic and Fiscal Policy (CEFP) seem to agree on the scope of drug price surveys for so-called “off-year” price revisions, but perhaps not on the scope of products actually facing revisions.…
To read the full story
Related Article
- PM Abe Watchful of Reward for Me-Too Drugs, CEFP Minutes Reveal
November 1, 2017
REGULATORY
- MHLW Taps Kawabata to Lead Drug Discovery Support Office
April 15, 2026
- MHLW Reviewing EMIS Data on Petro-Product Supply to Medical Institutions
April 15, 2026
- Japan Panel to Review Ferring Gene Therapy, Fujifilm Cell Product on April 20
April 14, 2026
- LDP, Ishin to Explore Role of Private Insurance in Reform Talks
April 14, 2026
- Middle East War Hitting API Air Freight, Trade Group Warns
April 13, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





